Dr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)

Similar documents
34-year-old female Presented with an 18-month history of headaches.

International Symposium on. Barcelona, May 5 th and 6 th 2011

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

Approach to HIV Associated Neurocognitive disorders (HAND)

Dr Sophia Davies. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)

Persistent low level viraemia on third line ART

Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?

HIV & Mental Health. Shaun Watson, Clinical Nurse Specialist (HIV. Community) Westminster, London. UK

Paediatric HIV Resistance Referal Pathway. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal

Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)

INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING

HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP

The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV

Overview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014

A Cerebellar Conundrum

Antiretroviral Treatment Strategies: Clinical Case Presentation

Issues of Neuropsychological Assessment in International Settings

GREENWOOD PUBLIC SCHOOL DISTRICT PHYSICAL EDUCATION

Dr Melanie Rosenvinge

What's new in the WHO ART guidelines How did markets react?

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

Caring for HIV infected patients in Spain during the current economical crisis

COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL

Case # 1. Case #1 (cont d)

How to Implement this Assessment in the Clinical Prac5ce?

Bonaventura Clotet. HIV Unit & Retroviroloy Lab Univ Hosp Germans Trias i Pujol Badalona, Catalonia, Spain

Difference of opinion? Michelle Moorhouse 24 Sep 2014

International Forum on HIV and Rehabilitation Research

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

Applying Improvement to Keep HIV+ Mothers and Exposed Infants in Care. Anisa Ismail Improvement Advisor University Research Co.

Dr Graham P Taylor Reader in Communicable Diseases

DSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City

Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Professor José Arribas

Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE

European Guidelines. for the Clinical Management and Treatment of HIV Infected Adults

Integrase Inhibitor Based Antiretroviral Therapy in Botswana; a Case Report

PD REHAB Trial Update. Cally Rick 8 th June 2010

UPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE

Clinical notes: Management of HAART in patients with HAND

Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Constructing antiretroviral regimens to overcome imperfect adherence

The CIDRZ Experience: use of data to understand patient outcomes and guide program implementation 07 January 2010

Integrated VL/EID& TB Data Review Meeting 23/3/2018 PIATO

BHIVA Best Practice Management Session

HIV associated CNS disease in the era of HAART

CAB 59: HIV and neurocogni5ve impairment

Assessment and management of dementia in relation to falls risk: Tools and tips for community, hospital and residential care

Dr Lucy Garvey. Imperial College Healthcare NHS Trust, London. 18 th Annual Conference of the British HIV Association (BHIVA)

Adolescents Living with HIV

BHIVA antiretroviral treatment guidelines 2015

Clinical skills building - HIV drug resistance

Management of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie

The Global Partnership for HIV-Free Survival (PHFS): Quality Improvement and Breastfeeding / ART compliance

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

Clinical cases: HIV/HCV coinfection

Cognitive impairment among Indonesia HIV naïve patients

Ewa Pietraszkiewicz Hospital for Infectious Diseases in Warsaw

Il ruolo della viremia nel management del paziente HIV. Carlo Federico Perno

Brighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer

APPENDIX A TASK DEVELOPMENT AND NORMATIVE DATA

Key issues in a transitional care service

London Therapeu-c Tender Implementa-on: Guidance for Clinical Use. 14 January 2015

Innovative diagnostics for HIV, HBV and HCV

BHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters

Lambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School

Education around PML risk and monitoring at NHNN Queen Square MS Centre

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz

All HIV-exposed Infants Should Receive Triple Drug Antiretroviral Prophylaxis. Against the motion

Monitoring of HIV positive mothers and HIV exposed infants in context of Option B+ implementation

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

Cryptococcal Meningitis

Mycobacterial Infections and HIV

Improving care of HIV-infected breastfeeding

Friday afternoon Programme

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England

HIV Clinical Nurse Specialist CCDHB Wellington

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER

ADVANCED CLINICAL CARE JOB AIDES VERSION1- MARCH 2018

Switching strategies and ARV treatment costs

Table 1: CD4 category by treatment regimens (reproduction of ASR report table specifically CD4 re categorisation of CD4) (a) (b) 2009.

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?

Visit 49 Training Document

Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients

Practical Scenarios Calculating doses for newborns. Karen Buckberry

WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?

Infertility Treatment and HIV

Treatment update. Bronagh McBrien June 2016

Diagnosis and Monitoring of HAND

BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi

PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT

HIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital

Dementia UK & Admiral Nurses

Rapid ART Program Initiative: How immediate ART initiation improves health outcomes

Transcription:

18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham

18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Dr Ria Daly: None declared Date April 2012 18-20 April 2012, The International Convention Centre, Birmingham

I think I m going crazy Virtual Clinic BHIVA Annual Conference 2012 Ria Daly

History 36yr female Cameroon 2003 UK 2005 Diagnosed HIV in London CD4 263 cells/mm 3 (13%), VL 88,619 copies/ml 2007 Relocated to B ham Not on ARVs CD4 213 cells/mm 3 (9%), VL 29,914 copies/ml No major mutations Subtype CRF02-AG PMH: Ophthalmic zoster 2006 SH: Traumatic events in Cameroon Psychologist PTSD

2007 Feb Struggling with diagnosis Low mood Concern regarding likely adherence May MDT support Improved mood Commenced Truvada & Nevirapine CD4 461 cells/mm 3 (16%) VL <40copies/ml

Date CD4 cells/mm 3 (%) Viral Load copies/ml Dec 08 504 (30) <40 Starts college Red cross locate children in Cameroon Apr 09 613 (34) <40 New partner Aug 09 502 (34) <40 Nov 09 453 (35) <40 Maintains good mental state, adherent Mar 10 532 (32) 43 Granted leave to remain Jun 10 671 (34) <20 Oct 10 507 (30) <20 Feb 11 593 (34) <20 Discloses to children Jun 11 558 (32) <20 Continues at college Keen to start working

Sept 2011 Letter from GP Memory loss & poor concentration Mind switches off Functional impact Noted over last few months by college tutor No new stressors. No signs of depression No focal weakness, systemically well Vit B12, TFTs normal Maintaining adherence

What would you do next? A) Re-explore psychosocial circumstances B) Neurocognitive assessment C) MRI head + lumbar puncture D) All of the above E) Other

A) Re-explore psychosocial circumstances

Neurocognitive Assessments Name of test What does it assess? How did our patient score? International HIV dementia scale (ihds) Hopkins verbal learning test revised (HVLT-R) Grooved pegboard nondominant hand test (GP Nondom) Verbal memory recall Motor speed Psychomotor speed Verbal learning memory (recall & recognition) 6/12 Interpretation? Motor Psychomotor Total recall: 1.8 SD below predicted mean Delayed recall: 1.35 SD below predicted mean Recognition Discrimination Index: 5.6 SDs below predicted mean. 4.5 SD below predicted mean

Frascati Criteria Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789 1799.

MRI Oct 2011 MRI & Lumbar Puncture CSF <1 WCC, no growth Glu 3 (plasma 4.5) Prot 0.24 Viral panel negative VDRL/TPPA negative Toxo PCR negative CSF VL <80 copies/ml Plasma VL 81 copies/ml

What would you do next? A) Continue current regimen B) Start antidepressants C) Change ARV regimen D) Other

BHIVA treatment guidelines (Draft 2012)

EACS Oct 2011

ARV modified What regimen would you use? A) TVD, DRV/r B) TVD, NVP, AZT C) TVD, NVP, MVC D) CBV, NVP, MVC E) Kivexa, Kaletra F) Kivexa, RAL G) Others?

ARV modified What regimen would you use? D) CBV, NVP, MVC

Did it make any difference? Subjectively - yes Started new college course Started work as a carer Making plans to travel to visit sons in Cameroon Objectively some improvement

Name of test Pre ARV change 6/52 post treatment change ihds 6/12 N/A Much less bradyphrenic Functionally improved HVLT-R Total recall: -1.8 SD Total recall: -2.3 SD Delayed recall: -1.35 SD Delayed recall: -1.35 SD Recognition Discrimination Index: - -5.6 SDs Recognition Discrimination Index: within 1 SD of predicted mean GP Nondom -4.5 SD -2 SD Colour trails 1 (speed of processing) Colour trails 2 (executive function) Within 1 SD of predicted mean -1.4 SD

Name of test Pre ARV change 6/52 post treatment change Now 6/12 post treatment change ihds 6/12 N/A Much less bradyphrenic Functionally improved HVLT-R Total recall: -1.8 SD Total recall: -2.3 SD N/A Social problems, low mood Still functionally improved Total recall: - 2.1 SD Delayed recall: -1.35 SD Delayed recall: -1.35 SD Delayed recall: -3.1 SD Recognition Discrimination Index: - -5.6 SDs Recognition Discrimination Index: within 1 SD of predicted mean Recognition Discrimination Index: within 1 SD of predicted mean GP Nondom -4.5 SD -2 SD -3.4 SD Colour trails 1 (speed of processing) Colour trails 2 (executive function) Within 1 SD of predicted mean -1.4 SD -2.5 SD -1.47 SD

With thanks to Elizabeth Stevens Claire Robertson Steve Taylor Next Case.